Acne, melasma, rosacea, pigmentation, hair loss, and dermatologic conditions.
Baricitinib, ritlecitinib, and deuruxolitinib are FDA approved for severe alopecia areata. Compare age limits, trials, boxed warnings, and evidence gaps.
Clascoterone is an FDA-approved topical androgen receptor inhibitor for acne. See the phase 3 results, limits, adverse effects, and unanswered comparisons.
Delgocitinib cream is FDA approved for some adults with chronic hand eczema. Review the phase 3 results, label limits, safety warnings, and evidence gaps.
Lebrikizumab and nemolizumab target different atopic dermatitis pathways. Compare their FDA labels, phase 3 designs, safety limits, and evidence gaps.
Ruxolitinib cream can improve facial repigmentation in some people with nonsegmental vitiligo. Review the FDA label, trial outcomes, timeline, and risks.
Erythema nodosum causes tender red nodules on the shins and often signals an underlying trigger. What causes it, how it is diagnosed, and how it is treated.
Why lasers and energy-based devices can trigger post-inflammatory hyperpigmentation, who is most at risk, and what the evidence supports to prevent and treat it.
What solar lentigines are, how they differ from other pigmented spots, and what the evidence supports for lasers, IPL, cryotherapy, peels, and topical agents.
What randomized trials and meta-analyses show about tranexamic acid for melasma, including efficacy by route (oral, topical, injected), safety, and who should avoid it.
How clinicians tell melasma, post-inflammatory hyperpigmentation, and solar lentigines apart, why it changes treatment and prognosis, and the evidence-based options for each.
What the evidence supports for male androgenetic alopecia: minoxidil, finasteride and dutasteride, adjunct options, and realistic expectations on results and risks.
A phenotype-based guide to rosacea: how flushing, persistent redness, papules and pustules, visible vessels, and eye involvement are treated, and why trigger control matters.
How topical retinoids work, how prescription tretinoin compares with retinaldehyde, retinol, and adapalene, and how to choose a tolerable option for aging or acne-prone skin.
How clinicians classify atrophic acne scars (ice-pick, boxcar, rolling) and what the evidence supports for subcision, fractional lasers, microneedling RF, and fillers.
What the evidence supports for treating common and plantar warts, why salicylic acid and cryotherapy are first-line, and when persistent warts need a different approach.
Why oral minoxidil at low dose has become a workhorse for female pattern hair loss, how Korean dermatology practices approach diagnosis and combination therapy, and what the evidence supports.
Why some patients on semaglutide or tirzepatide notice hair shedding, what pharmacovigilance and review data show, the likely telogen effluvium mechanism, and how it is managed.
Why adult-onset acne in women is often hormonally driven, how it differs from adolescent acne, and what the evidence supports for combined oral contraceptives, spironolactone, and topical therapy.
Evidence for FDA-approved hydroquinone + tretinoin + fluocinolone for melasma — efficacy vs monotherapy, adverse effects, and adjunctive options.